Metamorphosis

Metamorphosis-Tx is a biotechnology company dedicated to developing cancer differentiation therapies for aggressive and undifferentiated tumors. Founded in 2023 as a joint venture between DCDC-Tx and BioDetection Systems, the company leverages its proprietary STAP-STP and CALUX-STP platform technologies to quantitatively measure the activity of signal transduction pathways that regulate cell differentiation. By identifying drug combinations that induce undifferentiated cancer cells to mature into non-proliferative states, Metamorphosis-Tx aims to provide curative treatments for high-unmet-need indications such as glioblastoma, DIPG, and ovarian cancer. The company's approach integrates advanced AI-driven pathway analysis with companion diagnostics to enable precision oncology.